Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 20/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30178612 | 0.92 | TLR9 (0.38) | TLR9TLR7TLR8 | |
| SCHEMBL25601650 | 0.92 | TLR9 (0.38) | TLR9TLR7TLR8 | |
| SCHEMBL24838249 | 0.91 | IRAK4 (0.40) | TLR9TLR7TLR8 | |
| SCHEMBL30178642 | 0.85 | TLR9 (0.36) | TLR9TLR7TLR8 | |
| SCHEMBL25601652 | 0.85 | TLR9 (0.36) | TLR9TLR7TLR8 | |
| SCHEMBL30178976 | 0.84 | TLR9 (0.42) | TLR9TLR7TLR8 | |
| SCHEMBL24837707 | 0.84 | TLR9 (0.42) | TLR9TLR7TLR8 | |
| SCHEMBL23581053 | 0.79 | SMARCA2 (0.51) | TLR9TLR7TLR8 | |
| SCHEMBL23602194 | 0.78 | TLR9 (0.32) | TLR9TLR7TLR8 | |
| SCHEMBL23602793 | 0.78 | TLR9 (0.32) | TLR9TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | TLR9 3553/4885TLR7 3820/4885TLR8 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.